Altay Therapeutics, founded by Dr. Osman Ozes, focuses on developing small molecule drugs to treat chronic liver diseases such as liver fibrosis and liver cancer. The company's core mission is to create disease-modifying therapies that target transcription factors to reverse fibrosis and improve patient outcomes. Leveraging over 70 years of combined experience in small molecule drug development, Altay aims to replicate the success of Esbriet (Pirfenidone), the first FDA-approved therapy for lung fibrosis.

Notably, Dr. Osman Ozes, who led the development of Esbriet, co-founded Altay Therapeutics. Esbriet has become a significant commercial success, generating over $6 billion in revenue. Altay's team includes seasoned experts in drug development, contributing to its innovative approach and potential impact on chronic liver disease treatment. The company is poised to make substantial advancements in the medical field, potentially transforming the lives of patients suffering from debilitating liver conditions.